Si-Bone Financials
Si-Bone (SIBN) reported $200.9M in revenue for fiscal year 2025, up 20.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Sales growth is absorbing fixed costs, pushing cash burn near breakeven without leaning harder on the balance sheet today.
By FY2025, operating cash flow was almost flat at-$675K even though net loss was-$18.9M , showing that reported losses now consume far less cash than before. In FY2023, operating cash flow was still-$18.7M on a-$43.3M loss, so the two-year improvement reflects a business getting materially closer to self-funding as scale absorbs fixed costs.
The move toward breakeven came despite gross margin staying well below its earlier peaks: FY2025 was
Capital intensity is now the main reason cash is still negative: free cash flow was
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Si-Bone's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Si-Bone has an operating margin of -11.1%, meaning the company loses $11 on every $100 of revenue. This results in a profitability score of 28/100. This is up from -21.1% the prior year.
Si-Bone's revenue surged 20.2% year-over-year to $200.9M, reflecting rapid business expansion. This strong growth earns a score of 82/100.
Si-Bone carries a low D/E ratio of 0.20, meaning only $0.20 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 74/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 8.55, Si-Bone holds $8.55 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 96/100.
Si-Bone's operations used $675K of cash, and capex of $8.4M added to the outflow, for a free cash flow shortfall of $9.1M. This results in a cash flow score of 16/100.
Si-Bone posts a -10.7% return on equity (ROE), meaning it loses $11 for every $100 of shareholders' equity. This results in a returns score of 29/100. This is up from -18.5% the prior year.
Si-Bone scores 7.65, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($894.6M) relative to total liabilities ($61.0M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Si-Bone passes 6 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Si-Bone reported a net loss of $18.9M while operations used $675K of cash. With neither figure positive, the ratio between the two carries no quality signal.
Si-Bone reported an operating loss of $22.3M against $2.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Si-Bone generated $200.9M in revenue in fiscal year 2025. This represents an increase of 20.2% from the prior year.
Si-Bone's EBITDA was -$16.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 46.4% from the prior year.
Si-Bone reported -$18.9M in net income in fiscal year 2025. This represents an increase of 38.8% from the prior year.
Si-Bone earned -$0.44 per diluted share (EPS) in fiscal year 2025. This represents an increase of 41.3% from the prior year.
Cash & Balance Sheet
Si-Bone recorded an outflow of $9.1M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 60.3% from the prior year.
Si-Bone held $42.2M in cash against $35.6M in long-term debt as of fiscal year 2025.
Si-Bone paid $0.00 per share in dividends in fiscal year 2025.
Margins & Returns
Si-Bone's gross margin was 79.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.5 percentage points from the prior year.
Si-Bone's operating margin was -11.1% in fiscal year 2025, reflecting core business profitability. This is up 10.0 percentage points from the prior year.
Si-Bone's net profit margin was -9.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 9.1 percentage points from the prior year.
Si-Bone's ROE was -10.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 7.9 percentage points from the prior year.
Capital Allocation
Si-Bone invested $17.4M in research and development in fiscal year 2025. This represents an increase of 5.4% from the prior year.
Si-Bone invested $8.4M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 19.8% from the prior year.
Not reported for fiscal year 2025.
SIBN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $213.6M | $200.9M+20.2% | $167.2M+20.4% | $138.9M+30.5% | $106.4M+18.0% | $90.2M+22.8% | $73.4M+9.0% | $67.3M+21.5% | $55.4M+15.4% | $48.0M |
| Cost of Revenue | $43.7M | $41.0M+17.1% | $35.1M+19.0% | $29.5M+87.6% | $15.7M+50.6% | $10.4M+17.1% | $8.9M+31.1% | $6.8M+40.5% | $4.8M-5.5% | $5.1M |
| Gross Profit | $169.9M | $159.9M+21.0% | $132.1M+20.7% | $109.4M+20.6% | $90.7M+13.8% | $79.7M+23.6% | $64.5M+6.6% | $60.5M+19.7% | $50.5M+17.9% | $42.9M |
| R&D Expenses | $18.0M | $17.4M+5.4% | $16.6M+10.2% | $15.0M+10.3% | $13.6M+9.5% | $12.4M+31.5% | $9.5M+29.9% | $7.3M+35.4% | $5.4M-2.5% | $5.5M |
| SG&A Expenses | $40.0M | $40.5M+20.1% | $33.8M+8.6% | $31.1M+7.3% | $29.0M+15.5% | $25.1M+26.6% | $19.8M-5.6% | $21.0M+66.0% | $12.6M-3.2% | $13.1M |
| Operating Income | -$17.7M | -$22.3M+36.6% | -$35.2M+24.9% | -$46.9M+21.3% | -$59.6M-15.4% | -$51.7M-34.0% | -$38.6M-7.1% | -$36.0M-200.9% | -$12.0M+31.0% | -$17.4M |
| Interest Expense | $2.5M | $2.6M-23.6% | $3.4M-0.6% | $3.5M+22.8% | $2.8M-47.5% | $5.4M-12.1% | $6.1M+23.3% | $4.9M-3.1% | $5.1M-17.7% | $6.2M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | N/A | N/A | $0 | $0 |
| Net Income | -$14.6M | -$18.9M+38.8% | -$30.9M+28.6% | -$43.3M+29.4% | -$61.3M-8.3% | -$56.6M-29.5% | -$43.7M-13.8% | -$38.4M-120.0% | -$17.5M+24.2% | -$23.0M |
| EPS (Diluted) | — | -$0.44+41.3% | -$0.75+33.6% | -$1.13+36.9% | -$1.79-4.7% | -$1.71-14.0% | -$1.50 | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
SIBN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $238.6M+3.5% | $230.4M0.0% | $230.4M+46.3% | $157.6M-17.3% | $190.5M-14.6% | $223.1M+90.7% | $117.0M-15.5% | $138.5M+286.6% | $35.8M |
| Current Assets | $216.1M+4.0% | $207.8M-1.7% | $211.4M+53.6% | $137.6M-21.8% | $175.9M-19.4% | $218.2M+95.8% | $111.5M-18.1% | $136.0M+304.5% | $33.6M |
| Cash & Equivalents | $42.2M+20.9% | $34.9M+5.0% | $33.3M+60.6% | $20.7M-67.3% | $63.4M+18.4% | $53.6M+413.5% | $10.4M-58.5% | $25.1M+12.1% | $22.4M |
| Inventory | $33.9M+25.2% | $27.1M+33.7% | $20.2M+17.2% | $17.3M+50.3% | $11.5M+104.1% | $5.6M+3.3% | $5.5M+63.1% | $3.3M+30.9% | $2.6M |
| Accounts Receivable | $29.9M+8.9% | $27.5M+25.1% | $22.0M+6.2% | $20.7M+45.1% | $14.2M+4.7% | $13.6M+16.1% | $11.7M+38.1% | $8.5M+14.4% | $7.4M |
| Total Liabilities | $61.0M-3.9% | $63.5M+4.0% | $61.0M+3.0% | $59.3M+5.6% | $56.1M+4.3% | $53.8M-0.4% | $54.0M+11.7% | $48.3M-70.7% | $165.2M |
| Current Liabilities | $25.3M-6.8% | $27.1M+15.7% | $23.5M+10.8% | $21.2M+25.4% | $16.9M+25.4% | $13.5M-28.3% | $18.8M+108.5% | $9.0M+19.5% | $7.5M |
| Long-Term Debt | $35.6M+0.3% | $35.5M-1.7% | $36.1M+2.5% | $35.2M+0.6% | $35.0M-11.4% | $39.5M+13.2% | $34.9M-10.5% | $39.0M+0.7% | $38.7M |
| Total Equity | $177.5M+6.3% | $167.0M-1.4% | $169.4M+72.3% | $98.3M-26.9% | $134.4M-20.6% | $169.4M+168.8% | $63.0M-30.1% | $90.2M+169.7% | -$129.4M |
| Retained Earnings | -$450.3M-4.4% | -$431.4M-7.7% | -$400.4M-12.1% | -$357.1M-20.7% | -$295.8M-23.6% | -$239.3M-22.3% | -$195.6M-24.4% | -$157.2M-12.5% | -$139.7M |
Not reported in any period shown, so not listed: Goodwill.
SIBN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $2.5M | -$675K+94.6% | -$12.4M+33.6% | -$18.7M+55.1% | -$41.7M-5.4% | -$39.5M-28.9% | -$30.7M+3.1% | -$31.6M-117.8% | -$14.5M+17.2% | -$17.5M |
| Capital Expenditures | $6.9M | $8.4M-19.8% | $10.5M+34.6% | $7.8M-18.0% | $9.5M+48.8% | $6.4M+149.5% | $2.6M+4.7% | $2.4M+159.6% | $942K+97.1% | $478K |
| Free Cash Flow | -$4.4M | -$9.1M+60.3% | -$22.9M+13.5% | -$26.5M+48.2% | -$51.2M-11.4% | -$45.9M-38.2% | -$33.2M+2.5% | -$34.1M-120.4% | -$15.5M+14.1% | -$18.0M |
| Investing Cash Flow | -$6.0M | $4.2M-67.0% | $12.6M+121.1% | -$59.8M-2024.3% | -$2.8M-105.5% | $51.6M+182.0% | -$62.9M-566.4% | $13.5M+113.8% | -$97.8M-20365.5% | -$478K |
| Financing Cash Flow | $2.7M | $3.4M+72.4% | $2.0M-97.8% | $90.9M+4039.0% | $2.2M+228.4% | -$1.7M-101.3% | $136.4M+3810.6% | $3.5M-97.0% | $115.2M+795.3% | $12.9M |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $38K-47.9% | $73K | $0 |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
SIBN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 79.6%+0.5pp | 79.0%+0.3pp | 78.8%-6.5pp | 85.2%-3.2pp | 88.4%+0.6pp | 87.9%-2.0pp | 89.9%-1.4pp | 91.3%+1.9pp | 89.3% |
| Operating Margin | -11.1%+10.0pp | -21.1%+12.7pp | -33.8%+22.2pp | -56.0%+1.3pp | -57.3%-4.8pp | -52.5%+1.0pp | -53.5%-31.9pp | -21.6%+14.5pp | -36.2% |
| Net Margin | -9.4%+9.1pp | -18.5%+12.7pp | -31.2%+26.4pp | -57.6%+5.2pp | -62.8%-3.2pp | -59.5%-2.5pp | -57.1%-25.6pp | -31.5%+16.5pp | -48.0% |
| Return on Equity | -10.7%+7.9pp | -18.5%+7.1pp | -25.6%+36.8pp | -62.4%-20.3pp | -42.1%-16.3pp | -25.8%+35.2pp | -61.0%-41.6pp | -19.4% | N/A |
| Return on Assets | -7.9%+5.5pp | -13.4%+5.4pp | -18.8%+20.1pp | -38.9%-9.2pp | -29.7%-10.1pp | -19.6%+13.2pp | -32.8%-20.2pp | -12.6%+51.7pp | -64.3% |
| Current Ratio | 8.55+0.9x | 7.66-1.4x | 9.01+2.5x | 6.50-3.9x | 10.41-5.8x | 16.20+10.3x | 5.94-9.2x | 15.11+10.6x | 4.46 |
| Debt-to-Equity | 0.200.0x | 0.210.0x | 0.21-0.1x | 0.36+0.1x | 0.260.0x | 0.23-0.3x | 0.55+0.1x | 0.43 | N/A |
| FCF Margin | -4.5%+9.2pp | -13.7%+5.4pp | -19.1%+29.0pp | -48.1%+2.9pp | -50.9%-5.7pp | -45.3%+5.4pp | -50.6%-22.7pp | -27.9%+9.6pp | -37.5% |
Similar Companies
Where Si-Bone Ranks
Frequently Asked Questions
What is Si-Bone's annual revenue?
Si-Bone (SIBN) reported $200.9M in total revenue for fiscal year 2025. This represents a 20.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Si-Bone's revenue growing?
Si-Bone (SIBN) revenue grew by 20.2% year-over-year, from $167.2M to $200.9M in fiscal year 2025.
Is Si-Bone profitable?
No, Si-Bone (SIBN) reported a net income of -$18.9M in fiscal year 2025, with a net profit margin of -9.4%.
What is Si-Bone's EBITDA?
Si-Bone (SIBN) had EBITDA of -$16.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Si-Bone have?
As of fiscal year 2025, Si-Bone (SIBN) had $42.2M in cash and equivalents against $35.6M in long-term debt.
What is Si-Bone's gross margin?
Si-Bone (SIBN) had a gross margin of 79.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Si-Bone's operating margin?
Si-Bone (SIBN) had an operating margin of -11.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Si-Bone's net profit margin?
Si-Bone (SIBN) had a net profit margin of -9.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Si-Bone's return on equity (ROE)?
Si-Bone (SIBN) has a return on equity of -10.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Si-Bone's free cash flow?
Si-Bone (SIBN) recorded an outflow of $9.1M in free cash flow during fiscal year 2025. This represents a 60.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Si-Bone's operating cash flow?
Si-Bone (SIBN) recorded an outflow of $675K in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Si-Bone's total assets?
Si-Bone (SIBN) had $238.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Si-Bone's capital expenditures?
Si-Bone (SIBN) invested $8.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Si-Bone spend on research and development?
Si-Bone (SIBN) invested $17.4M in research and development during fiscal year 2025.
What is Si-Bone's current ratio?
Si-Bone (SIBN) had a current ratio of 8.55 as of fiscal year 2025, which is generally considered healthy.
What is Si-Bone's debt-to-equity ratio?
Si-Bone (SIBN) had a debt-to-equity ratio of 0.20 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Si-Bone's return on assets (ROA)?
Si-Bone (SIBN) had a return on assets of -7.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Si-Bone's cash runway?
Based on fiscal year 2025 data, Si-Bone (SIBN) had $42.2M in cash against an annual operating cash burn of $675K. This gives an estimated cash runway of approximately 751 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Si-Bone's Altman Z-Score?
Si-Bone (SIBN) has an Altman Z-Score of 7.65, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Si-Bone's Piotroski F-Score?
Si-Bone (SIBN) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Si-Bone's earnings high quality?
Si-Bone (SIBN) reported a net loss of $18.9M while operations used $675K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Si-Bone cover its interest payments?
Si-Bone (SIBN) reported an operating loss of $22.3M against $2.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Si-Bone?
Si-Bone (SIBN) scores 54 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.